This company listing is no longer active
MGC Pharmaceuticals 과거 수익 실적
과거 기준 확인 0/6
MGC Pharmaceuticals's earnings have been declining at an average annual rate of -17.9%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 36% per year.
주요 정보
-17.9%
수익 성장률
2.0%
EPS 성장률
Pharmaceuticals 산업 성장 | 31.2% |
매출 성장률 | 36.0% |
자기자본 수익률 | n/a |
순이익 | -614.7% |
최근 수익 업데이트 | 30 Jun 2023 |
최근 과거 실적 업데이트
업데이트 없음
Recent updates
수익 및 비용 분석
MGC Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 23 | 3 | -21 | 15 | 0 |
31 Mar 23 | 4 | -22 | 15 | 0 |
31 Dec 22 | 5 | -23 | 15 | 0 |
30 Sep 22 | 5 | -22 | 13 | 0 |
30 Jun 22 | 5 | -20 | 12 | 0 |
31 Mar 22 | 5 | -19 | 11 | 0 |
31 Dec 21 | 5 | -18 | 10 | 0 |
30 Sep 21 | 4 | -17 | 9 | 0 |
30 Jun 21 | 3 | -16 | 8 | 0 |
31 Dec 20 | 1 | -13 | 5 | 0 |
30 Sep 20 | 2 | -16 | 6 | 0 |
30 Jun 20 | 2 | -19 | 7 | 0 |
31 Dec 19 | 2 | -18 | 7 | -1 |
30 Sep 19 | 1 | -14 | 6 | 0 |
30 Jun 19 | 1 | -11 | 6 | 0 |
31 Dec 18 | 1 | -7 | 5 | 1 |
30 Sep 18 | 0 | -7 | 5 | 1 |
30 Jun 18 | 0 | -8 | 5 | 1 |
31 Mar 18 | 0 | -10 | 6 | 1 |
31 Dec 17 | 0 | -12 | 6 | 0 |
30 Sep 17 | 0 | -10 | 6 | 0 |
30 Jun 17 | 0 | -8 | 7 | 0 |
31 Mar 17 | 0 | -7 | 5 | 0 |
31 Dec 16 | 0 | -6 | 4 | 0 |
30 Sep 16 | 0 | -6 | 3 | 0 |
30 Jun 16 | 0 | -6 | 2 | 0 |
31 Mar 16 | 0 | -6 | 2 | 0 |
31 Dec 15 | 0 | -6 | 1 | 0 |
30 Sep 15 | 0 | -5 | 1 | 0 |
30 Jun 15 | 0 | -4 | 1 | 0 |
31 Mar 15 | 0 | -5 | 1 | 0 |
31 Dec 14 | 0 | -6 | 1 | 0 |
30 Sep 14 | 0 | -6 | 1 | 0 |
30 Jun 14 | 0 | -5 | 0 | 0 |
31 Mar 14 | 0 | -3 | 0 | 0 |
31 Dec 13 | 0 | 0 | 0 | 0 |
30 Sep 13 | 0 | -1 | 0 | 0 |
30 Jun 13 | 0 | -1 | 1 | 0 |
31 Mar 13 | 0 | -1 | 0 | 0 |
31 Dec 12 | 0 | -1 | 0 | 0 |
양질의 수익: MXCDA is currently unprofitable.
이익 마진 증가: MXCDA is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: MXCDA is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.
성장 가속화: Unable to compare MXCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: MXCDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
자기자본 수익률
높은 ROE: MXCDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.